Breaking research, regulatory updates, and industry developments in the world of peptide science.
The FDA has released updated guidance on the compounding of semaglutide and tirzepatide, impacting pharmacies and patients nationwide. The new regulations aim to balance patient access with safety standards.
Eli Lilly's triple agonist retatrutide demonstrated unprecedented 24% body weight reduction in Phase 3 trials, surpassing existing GLP-1 therapies and setting a new benchmark for obesity treatment.
New data from Novo Nordisk's oral semaglutide formulation shows comparable efficacy to injectable versions, potentially revolutionizing patient compliance and accessibility in diabetes management.
A landmark Phase 2 clinical trial for BPC-157 in inflammatory bowel disease has commenced, marking the first major clinical study of this peptide in a gastrointestinal indication.
A comprehensive study published in Nature Aging demonstrates that specific peptide combinations can significantly improve biomarkers associated with cellular aging and telomere length.
Several states have introduced new legislation restricting the sale and distribution of compounded peptide therapies, raising concerns among patients and practitioners about continued access.